ddx-35 Antibody

Clarification of Terminology

The term "ddx-35" does not align with nomenclature conventions for antibodies or their targets. Antibodies are typically named after their target antigens (e.g., CD35, DDX3) or clone identifiers (e.g., C-4).

• Possible misinterpretations:

  • CD35: Sources discuss CD35 (cluster of differentiation 35), a complement receptor used in diagnosing chronic lymphocytic leukemia (CLL). This is unrelated to "ddx-35."

  • DDX3 Antibody (C-4): Source describes DDX3 Antibody (C-4), targeting DEAD box helicases DDX3X/DDX3Y, which regulate RNA metabolism and viral replication.

DDX3 Antibody (C-4) (Source )

Antibody Panels and Diagnostic Use Cases

Sources highlight standardized antibody panels for clinical diagnostics:

• CD35 in CLL Diagnosis:

  • Reduced CD35 expression (<17%) distinguishes CLL from other B-cell malignancies (sensitivity: 81.8%, specificity: 88.4%) .

  • Improves the Matutes score’s discriminative power (accuracy increased from 96.6% to 97.6%) .

• EuroFlow Panels:

  • Acute leukemia orientation tubes (ALOT) integrate markers like CD45, CD34, and CD19 to classify malignancies .

• Viral Antibody Profiling:

  • Source identifies six anti-EBV antibodies (e.g., BLRF2-IgA, BDLF1-IgG) for nasopharyngeal carcinoma diagnosis.

Antibody Validation and Assays

• Preclinical/Clinical Assays: Source evaluates gene therapy antibodies (e.g., AAV5) using ELISA and neutralization assays.

• ZIKV/DENV Antibody Panels: Source validates a five-antibody panel for viral differentiation (specificity >90%).